Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

411 - Clinical feasibility of EGFR mutation detection by CastPCR in plasma cell-free DNA of lung adenocarcinoma patients

Date

17 Dec 2016

Session

Poster lunch

Presenters

Yang Yang

Citation

Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574

Authors

Y. Yang, Z. Hang, S. Xiaoyan, Y. Lixia, L. Baorui, W. Lifeng

Author affiliations

  • The Comprehensive Cancer Center Of Drum‐tower Hospital., Affiliated Drum Tower Hospital Nanjing University, 210008 - Nanjing/CN
More

Resources

Abstract 411

Background

CastPCR is a newly developed gene analysis assay with high sensitivity and specificity. Multiple studies have demonstrated that CastPCR is superior in gene analysis of tumor tissue compared with other assays such as Sanger sequencing and ARMS. In previous experiments, we have identified the sensitivity of CastPCR in detection of EGFR mutation-known lung cancer cell lines mimicing that of peripheral blood: 0.1% in exon 19 deletion (Del19), L858R in exon 21 and 1% in T790M in exon 20. Since there is difficulty in obtaining tumor tissue from late-staged lung cancer patients and the infeasibility of repeated biopsy and dynamic monitoring during targeted therapy, a complementary method is badly needed.

Methods

107 FFPE tissue samples of treatment-naive lung adenocarcinoma patients and matched peripheral blood were collected. CastPCR was used to analysis the EGFR mutation status (exon 19 del2235-2249, del2236-2250, exon 20 T790M and exon 21 L858R) both in the FFPE samples and the peripheral blood. Feasibility-identifying parameters including sensitivity, specificity, positive predictive value, negative predictive value and the concordance was calculated, respectively.

Results

1. In FFPE samples, 51.4% (55/107) were EGFR mutation-positive: 37.4% (40/107) harbored EGFR sensitizing mutations (Del 19 or/and L858R) and 18.7% (20/107) harbored EGFR resistant mutations (T790M), and 5.6% (6/107) harbored double mutations in the same sample. 2. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and the concordance of EGFR mutation detection in cfDNA by CastPCR was shown in the table.rn

Table: 51P Parameters of mutation analysis

rnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrnrn
ParametersEGFRT790M19Del & L858R
Sensitivity56.4% (31/55)45.0% (9/20)57.5% (23/40)
Specificity94.2% (49/52)100.0% (87/87)95.5% (64/67)
PPV91.2% (31/34)100.0% (9/9)88.5% (23/26)
NPV67.1% (49/73)88.8% (87/98)79.0% (64/81)
Concordance74.8% (80/107)89.7% (96/107)81.3% (87/107)
rn

PPV: Positive Predictive Value; NPV: Negative Predictive Value

rn

Conclusions

CastPCR can not only effectively detect the EGFR mutation statues in tumor FFPE samples, but also can confer clinical feasibility of EGFR mutation analysis in cfDNA.

Clinical trial indentification

Legal entity responsible for the study

Lifeng Wang

Funding

1. the Health Scientific Research Project of Jiangsu Province, Nanjing, China (grant no. H201235); 2. Key Project of Nanjing Medical Science and Technology Development Foundation, Nanjing, China (grant no. ZKX12012).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings